Anjali Arora
5 Papers
16 Citations
Anjali Arora is an academic researcher. The author has contributed to research in topics: Familial hypercholesterolemia & Population. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Metabolic syndrome and cardiovascular disease in South Asians.
TL;DR: The prevalence of metabolic syndrome and cardiovascular disease in the South Asian population is discussed, conventional and emerging risk factors are evaluated, and the need for ethnic-specific redefinition of guidelines used to diagnose metabolic syndrome is reinforced.
Spectrum of mutations in homozygous familial hypercholesterolemia in India, with four novel mutations.
TL;DR: The spectrum of mutations in cases of homozygous FH in Asian Indians is quite heterogeneous and 40% were novel, while an interesting "Triple hit" case with features of homogeneous FH is reported.
20
Genetic analysis of familial hypercholesterolemia in Asian Indians: a single center study
Nitika Setia,Sireesha Movva,Prahlad Balakrishnan,Ishpreet K. Biji,Jitendra Pal Singh Sawhney,Raman Puri,Anjali Arora,Ratna Dua Puri,Renu Saxena,Sanghamitra Mishra,Sanika Apte,Samarth Kulshrestha,V. L. Ramprasad,Ishwar C. Verma +13 more
TL;DR: Next-generation sequencing technology helped identify new mutations in APOB gene, suggesting that in less-studied populations, it is better to sequence the whole gene rather than test for specific mutations.
16
Targeting mulitple dyslipidemias with fixed combinations – focus on extended release niacin and simvastatin
TL;DR: The biochemical mechanisms of action and clinical uses for simvastatin and niacin are discussed, and the combination of these agents in the management and treatment of dyslipidemia is discussed.
14
Growing Cardiovascular and Metabolic Diseases in the Developing Countries: Is there a Role for Small Dense LDL Particles as an Inclusion Criteria for Individuals at Risk for the Metabolic Syndrome?
TL;DR: The role of LDL cholesterol as a cause and effect of complications with the metabolic syndrome in patients of countries that are developing cardiovascular and metabolic diseases at an accelerated rate is explored.
3